Q-omics provides the consensus-scored SNORA41B profile across patient tissues and cancer cell-line models. SNORA41B expression is associated with patient survival in 5 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, SNORA41B is differentially expressed in 2, with the highest sampling consensus in PRAD. Additionally, SNORA41B RNA expression shows 5,262 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight SKCM, PRAD, and STAD as cancer lineages where SNORA41B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA41B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA41B survival associations across molecular data types. SNORA41B RNA expression shows survival associations in the most cancer types (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA41B RNA expression–survival associations across cancer types. High SNORA41B expression shows unfavorable associations in SKCM, THYM, THCA, LUSC and UCEC. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for SNORA41B RNA expression.
This table summarizes SNORA41B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA41B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA41B shows higher tumor expression in PRAD and LUAD. The PRAD box plot shows higher SNORA41B RNA expression in tumor versus normal tissue (log2 FC = +0.498, t-test p < 0.001).
This table shows molecular features associated with SNORA41B in patient tissues and cancer cell lines. In patient samples, SNORA41B shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
